Harder S - Search Results

1

Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: Potential for drug-drug interactions.

Riess H, Prandoni P, Harder S, Kreher S, Bauersachs R. Riess H, et al. Among authors: harder s. Crit Rev Oncol Hematol. 2018 Dec;132:169-179. doi: 10.1016/j.critrevonc.2018.09.015. Epub 2018 Sep 29. Crit Rev Oncol Hematol. 2018. PMID: 30447923 Review.

2

Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease.

Klinkhardt U, Bauersachs R, Adams J, Graff J, Lindhoff-Last E, Harder S. Klinkhardt U, et al. Among authors: harder s. Clin Pharmacol Ther. 2003 Mar;73(3):232-41. doi: 10.1067/mcp.2003.13. Clin Pharmacol Ther. 2003. PMID: 12621388

3

Clinically important drug interactions with anticoagulants. An update.

Harder S, Thürmann P. Harder S, et al. Clin Pharmacokinet. 1996 Jun;30(6):416-44. doi: 10.2165/00003088-199630060-00002. Clin Pharmacokinet. 1996. PMID: 8792056 Review.

4

Renal profiles of anticoagulants.

Harder S. Harder S. J Clin Pharmacol. 2012 Jul;52(7):964-75. doi: 10.1177/0091270011409231. Epub 2011 May 24. J Clin Pharmacol. 2012. PMID: 21610202 Review.

5

Thrombolytics: drug interactions of clinical significance.

Harder S, Klinkhardt U. Harder S, et al. Drug Saf. 2000 Nov;23(5):391-9. doi: 10.2165/00002018-200023050-00004. Drug Saf. 2000. PMID: 11085346 Review.

6

Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.

Graff J, Harder S. Graff J, et al. Among authors: harder s. Clin Pharmacokinet. 2013 Apr;52(4):243-54. doi: 10.1007/s40262-013-0034-0. Clin Pharmacokinet. 2013. PMID: 23389892 Review.

7

Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation.

Ujeyl M, Köster I, Wille H, Stammschulte T, Hein R, Harder S, Gundert-Remy U, Bleek J, Ihle P, Schröder H, Schillinger G, Zawinell A, Schubert I. Ujeyl M, et al. Among authors: harder s. Eur J Clin Pharmacol. 2018 Oct;74(10):1317-1325. doi: 10.1007/s00228-018-2504-7. Epub 2018 Jun 16. Eur J Clin Pharmacol. 2018. PMID: 29909576

8

Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism.

Harder S. Harder S. Thromb J. 2014 Oct 28;12:22. doi: 10.1186/1477-9560-12-22. eCollection 2014. Thromb J. 2014. PMID: 25698904 Free PMC article. Review.

9

Novel oral anticoagulants: clinical pharmacology, indications and practical considerations.

Harder S, Graff J. Harder S, et al. Eur J Clin Pharmacol. 2013 Sep;69(9):1617-33. doi: 10.1007/s00228-013-1510-z. Epub 2013 Apr 26. Eur J Clin Pharmacol. 2013. PMID: 23619611 Review.

10

Differences in the quality of oral anticoagulation therapy with vitamin K antagonists in German GP practices - results of the cluster-randomized PICANT trial (Primary Care Management for Optimized Antithrombotic Treatment).

Mertens C, Siebenhofer A, Berghold A, Pregartner G, Ulrich LR, Mergenthal K, Kemperdick B, Schulz-Rothe S, Rauck S, Harder S, Gerlach FM, Petersen JJ. Mertens C, et al. Among authors: harder s. BMC Health Serv Res. 2019 Aug 1;19(1):539. doi: 10.1186/s12913-019-4372-y. BMC Health Serv Res. 2019. PMID: 31370840 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

506 results

Search Page